Company Announcement - Aligos Therapeutics, Inc. has appointed David Perry as Vice President of Business Development, effective immediately [1] - The company aims to maximize the potential of its pipeline, including ALG-055009, which has recently shown positive topline data [1] Leadership Background - David Perry brings over 20 years of experience in the life sciences industry, focusing on corporate strategy, business development, and investment management [1][2] - His previous role was Senior Director of Business Development at Sangamo Therapeutics, where he led significant licensing deals [1][2] - Perry has also held positions at Apexigen Inc. and Sumitomo Chemical, contributing to M&A and early-stage investments [2] Company Overview - Aligos Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for liver and viral diseases [3] - The company employs a science-driven approach to advance its pipeline targeting metabolic dysfunction-associated steatohepatitis (MASH) and high unmet medical needs such as hepatitis B and coronaviruses [3]
Aligos Therapeutics Appoints David Perry as Vice President of Business Development